Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism.

Scientists studied a supplement called acetyl-L-carnitine (ALC) in rats with autism-like behaviors. They found that ALC helped improve behavior problems by supporting gut health and reducing brain inflammation. The treatment increased beneficial bacteria products in the gut and strengthened the intestinal lining, which led to less inflammation throughout the body and brain.

This study investigated acetyl-L-carnitine (ALC) treatment in a valproate-induced autism rat model. Researchers found that prenatal valproate exposure caused autism-like behaviors, reduced beneficial gut bacteria metabolites (SCFAs), compromised intestinal barrier function, and increased brain inflammation. Treatment with ALC from postnatal days 23-51 significantly improved these deficits by restoring gut microbiota-derived SCFAs, strengthening intestinal barriers, and reducing neuroinflammation and microglial activation in the cerebral cortex. The study suggests a potential gut-brain axis mechanism where ALC therapy may alleviate autism-associated behaviors through improvements in gut health and subsequent reductions in systemic and brain inflammation.

Results suggest ALC may benefit autism through gut-brain axis modulation, potentially addressing both behavioral symptoms and gastrointestinal comorbidities. However, human clinical trials are needed before considering therapeutic applications. The gut microbiome connection warrants further investigation in autism treatment approaches.

Animal study only - findings may not translate to humans. Sample size not reported. Single intervention dose tested. Limited to one autism model (valproate). No long-term follow-up data provided.

Autism spectrum disorder is characterized by a variety of cellular and molecular abnormalities which leads to autism-associated behaviors. Besides behavioral defects, these individuals also suffer from various associated disorders such as gastrointestinal deficit, altered gut microbiota composition and their metabolite. This study examined the effect of ALC on microbiota SCFA production and its effects on brain inflammation in VPA autism model. After prenatal exposure to valproate (600 mg/kg, i.p.) on embryonic day 12.5, followed by ALC treatment (100 mg/kg during postnatal days 23-51, p.o.), ASD-like behaviors, SCFAs amount in feces, intestine integrity (Occludin and ZO-1 tight junction proteins), systemic and brain inflammation (TNF-α and IL-1β) were assessed.

Then, Golgi-Cox staining and Western blot for Iba1 protein were utilized to identify the changes in microglia profile in cerebral cortex. In the VPA model, we found that induction of autism was associated with demoted levels of SCFAs in feces and disintegration of intestine tissue which led to elevated level of TNF-α in the plasma. Further, we characterized an increased number of microglia in our histology evaluation and Iba1 protein in cerebral cortex. We also observed elevated level of TNF-α and IL-1β in the cerebral cortex of VPA rat.

All these abnormalities were significantly alleviated by ALC treatment. Overall, our findings suggest that alleviation of behavioral abnormalities by ALC therapy in the VPA model of autism is associated with an improvement in the gut microbiota SCFAs, intestinal barrier and recovery of microglia and inflammation in the brain.